We have deepened the understanding of the influence of CD163 on CRC prognosis and also the possible effects on 22 types of lymphocytes, tumor purity, immune check-points such as PD-L1, and the potential involvement of CD163 in different CRC-relevant cancer hallmark pathways and biological processes. This evidence concerns the gene CD163 and cancer.